465 related articles for article (PubMed ID: 27097113)
21. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
24. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
25. CD20 antibodies induce production and release of reactive oxygen species by neutrophils.
Werlenius O; Riise RE; Simpanen M; Aurelius J; Thorén FB
Blood; 2014 Jun; 123(25):4001-2. PubMed ID: 24948624
[No Abstract] [Full Text] [Related]
26. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract][Full Text] [Related]
27. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
28. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
[TBL] [Abstract][Full Text] [Related]
29. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
30. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.
Collier-Bain HD; Emery A; Causer AJ; Brown FF; Oliver R; Dutton D; Crowe J; Augustine D; Graby J; Leach S; Eddy R; Rothschild-Rodriguez D; Gray JC; Cragg MS; Cleary KL; Moore S; Murray J; Turner JE; Campbell JP
Brain Behav Immun; 2024 May; 118():468-479. PubMed ID: 38503395
[TBL] [Abstract][Full Text] [Related]
31. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
[TBL] [Abstract][Full Text] [Related]
32. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
[TBL] [Abstract][Full Text] [Related]
34. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
35. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
36. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
[TBL] [Abstract][Full Text] [Related]
40. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
Rudnicka D; Oszmiana A; Finch DK; Strickland I; Schofield DJ; Lowe DC; Sleeman MA; Davis DM
Blood; 2013 Jun; 121(23):4694-702. PubMed ID: 23613524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]